1. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans 
James F. List, Jean M. Whaley 
Kidney International 
Volume 79, Pages S20-S27 (March 2011)
DOI: /ki
Copyright © 2011 International Society of Nephrology Terms and Conditions

2. Figure 1
Dose-dependent glucosuric response of selected SGLT2 inhibitors over 24h per 200g body weight following oral administration in normal rats. Data are not from a single head-to-head study.5,6
Adapted with permission from Meng et al.6 Copyright 2008, American Chemical Society.
Kidney International  , S20-S27DOI: ( /ki )
Copyright © 2011 International Society of Nephrology Terms and Conditions

3. Figure 2
Phlorizin increases insulin-mediated glucose uptake in diabetic rats during a two-step euglycemic hyperinsulinemic clamp study. (a) Glucose uptake during insulin infusion rate of 2.4mU/kg·min. (b) Glucose uptake during insulin infusion rate of 4.8mU/kg·min (ref. 10).
Kidney International  , S20-S27DOI: ( /ki )
Copyright © 2011 International Society of Nephrology Terms and Conditions

4. Figure 3
Dose-dependent increases in urinary glucose excretion with dapagliflozin or sergliflozin in 64 or 14 healthy volunteers, respectively. (a) Dapagliflozin data;31 copyright 2009, American Society for Clinical Pharmacology and Therapeutics. (b) Sergliflozin data;32 copyright American Diabetes Association.
Kidney International  , S20-S27DOI: ( /ki )
Copyright © 2011 International Society of Nephrology Terms and Conditions

5. Figure 4
Urinary glucose excretion in 6 healthy subjects and 16 patients with type 2 diabetes mellitus (T2DM) after 1 and 14 days of treatment with dapagliflozin (100mg). Circles represent observed values and bars represent median values.30 Copyright 2009, American Society for Clinical Pharmacology and Therapeutics.
Kidney International  , S20-S27DOI: ( /ki )
Copyright © 2011 International Society of Nephrology Terms and Conditions

6. Figure 5
Mean change in fasting plasma glucose over time in 389 treatment-naive patients with type 2 diabetes mellitus treated with dapagliflozin.38 NS, not significant.
Copyright 2009, American Diabetes Association.
Kidney International  , S20-S27DOI: ( /ki )
Copyright © 2011 International Society of Nephrology Terms and Conditions